USA Equities Corp (OTCMKTS:USAQ) Stock In Focus After Reporting Q4 Results
Digital healthcare company focusing on providing clinicians with AI tools, USA Equities Corp (OTCMKTS:USAQ) on April 5, 2022, announced financial results for quarter four as well as the entire year 2021.
Market Stats
On Tuesday, USAQ stock ended flat at $0.55 with more than 105 shares, compared to its average volume of 1.1K shares. The stock moved within a range of $0.5500 – 0.5500 after opening trading at $0.55.
USAQ CEO Troy Grogan said that the $1.6 million acquisition of AllergiEnd assets in June 2021 has made a strong strategic platform to build upon in 2022 and beyond.
Revenue generated from sales of AllergiEnd was $329,989 in quarter four of 2021 vis-à-vis $124,532 for the same period in 2020. Additionally, the company’s physician practice clients generated about $5,000,000 in revenues. Grogan added that it’s a large benefit to clients in the current climate of reducing reimbursements for primary care physicians.
The CEO further said that 163 medical practices were given 11,235 patients with allergy diagnostic tests resulting in $3.8 million in new reimbursements. Furthermore, physicians gave allergen immunotherapy treatments to 1,019 patients resulting in about $1.2 million in new reimbursements for customers.
It is estimated that harnessing AllergiEnd and QHSLab lead to an extra 5-10% income. Some of the 163 practices harnessed its products at the start of 2021. The firm’s services and products may be allowing practices to achieve higher income levels above 10% compared to nonutilisation of its platform, services and products.
Traders Corner
USAQ stock is trading below the 10-Day and 50-Day Moving averages of $0.55 and $0.56 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.69.
